By John W.M. Claud and Michelle L. Butler, Hyman, Phelps & McNamara
Mounting concerns that FDA reviewers could start missing PDUFA deadlines have put many on edge. The moment calls for defensive and offensive strategies.
Looking to avoid unnecessary delays and costly rework? Check out this webinar that shares important considerations for embarking on a new drug development program. Watch now!
Explore the potential of targeting LILRB2/LILRB4 in cancer immunotherapy by delving into our findings on novel monoclonal antibodies that enhance anti-tumor immune responses.
When preparing for IND submission, developers must consider multiple components. Explore tips for optimizing your early development program and the benefits of housing all activities under one roof.
Wastewater incineration reduction and solvent recovery are two sustainable process techniques that can be built into the drug manufacturing workflow to significantly reduce carbon emissions and waste.
See how PBPK models combined with custom and off-the-shelf in vitro tools and solubility enhancement expertise can reduce the need for drug product reformulation or repeated preclinical or clinical studies.
